Melanoma Monday: Military members at risk; sleep apnea may worsen outcomes
Click Here to Manage Email Alerts
Today is Melanoma Monday.
The American Academy of Dermatology established the observance — which falls on the first Monday of May — to raise awareness about causes and symptoms of melanoma, the deadliest form of skin cancer.
The effort also emphasizes the importance of sun protection and other strategies to reduce melanoma risk.
In conjunction with Melanoma Monday, Healio presents the following updates in melanoma research and treatment:
1. The FDA approved lifileucel (Amtagvi, Iovance Biotherapeutics) in February for treatment of advanced melanoma. In a Healio Exclusive, researchers who have focused on development of tumor-infiltrating lymphocytes offer insights into the impact of the approval for melanoma treatment and look ahead to the potential of this modality for treatment of other tumor types. Read more.
2. Clinicians treating patients with tumor-infiltrating lymphocytes should closely monitor toxicities associated with interleukin-2 and halt administration of the drug if necessary, according to the first guidelines regarding the therapy. Read more.
3. Use of immune checkpoint inhibitors for pregnant women with melanoma or other types of cancer may be safer than previously thought. Read more.
4. Untreated moderate to severe obstructive sleep apnea increased risk for poor long-term prognosis among people with melanoma. Read more.
5. Older adults and men exhibited higher risk for second primary melanoma diagnosis than other patients treated for that type of skin cancer. Read more.
6. Metabolic changes can be identified in patients with advanced melanoma by imaging tumors within 1 week of beginning immunotherapy. Read more.
7. Despite the high cure rate of localized cutaneous melanoma, many patients who undergo successful surgical resection experience severe anxiety and fear about the possibility of recurrence. Read more.
8. U.S. military members face an increased risk for developing melanoma due to occupational hazards. Read more.
9. The percentage of patients with advanced melanoma or other malignancies who died within a month of beginning immunotherapy rose significantly in the last decade. Read more.
10. Chronic immune-associated adverse events appeared common after treatment with adjuvant anti-PD-1 therapy among patients with melanoma. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts